Protein Binding Alters the Activity of Suramin, Carboxyamidotriazole, and UCN-01 in an ex Vivo Rat Aortic Ring Angiogenesis Assay

Angiogenesis inhibitors are currently in clinical development for cancer. These agents pose unique developmental challenges: ( a ) determining maximum biological doses versus maximum tolerated doses; ( b ) defining response criteria other than objective tumor responses; and ( c ) defining safe regim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2001-07, Vol.7 (7), p.1867-1872
Hauptverfasser:	KRÜGER, Erwin A, FIGG, William D
Format:	Artikel
Sprache:	eng
Schlagworte:	Alkaloids - metabolism Alkaloids - pharmacology Angiogenesis Inhibitors - metabolism Angiogenesis Inhibitors - pharmacology Animals Antineoplastic agents Aorta, Thoracic - drug effects Aorta, Thoracic - pathology Biological and medical sciences Biological Assay - methods Blood Proteins - metabolism Blood Proteins - pharmacology Chemotherapy Dose-Response Relationship, Drug Humans In Vitro Techniques Male Medical sciences Neovascularization, Pathologic - prevention & control Pharmacology. Drug treatments Protein Binding Rats Rats, Sprague-Dawley Staurosporine - analogs & derivatives Suramin - metabolism Suramin - pharmacology Triazoles - metabolism Triazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!